Prospective Study Finds Potential Utility of MeMed’s Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients

NEXT STORY
BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS
PREV STORY
First half of the year with 1%1 growth at constant exchange rates, significant impact of COVID-19 pandemic
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

IndustryBriefs

Compiled by Latesha Richards   Time Inc. Rebrands Time Inc.’s Targeted Marketing Division is ...

PM360 Staff
PM360 Staff

Navigating the Challenges of Biopharma Product Launches: A Blueprint for Success

Embarking on the journey from product development to market success in the biopharma industry ...

Nancy Phelan
Nancy Phelan

Where Healthcare for Women Must Go Now

Surprisingly, the subject of women’s health, bodies and care is no longer simply a ...

Meg Columbia-Walsh
Meg Columbia-Walsh